Os efeitos da Trazodona na cognição humana: uma revisão sistemática

• Autor(a) principal: Ana Mafalda Gonçalves Gonçalo
• Data de Publicação: 2021
• Tipo de documento: Dissertação
• Idioma: eng
• Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
• Texto Completo: https://hdl.handle.net/10216/134547
• topic: Ciências médicas e da saúde; Medical and Health sciences

Trazodone is a widely used antidepressant, also useful in the control of agitation and insomnia in Alzheimer's disease. It is now recognized a new mechanism of action for trazodone, based on its effect on the Unfolded Protein Response (UPR) pathway, restoring protein translation and slowing neurodegenerative progression in mice. These mechanisms may be seen as promising in dementia modifying treatment. To explore the effects of trazodone on human cognition and search for clinical evidence of its putative benefits in human's neurodegenerative diseases, a systematic review was conducted for studies that evaluated the effect of a minimum of 25 mg of trazodone daily, for at least one week, in the cognition of healthy or diseased patients with eighteen years or more. The search was run in MEDLINE, Web of Science, and CENTRAL from Cochrane databases, yielding a total of 16 studies, after selection. Overall, seven studies showed no effect of trazodone on cognition, five showed a beneficial effect by improving or reducing cognitive decline and four evidenced impaired cognitive function. Our analysis highlights the possibility of a dose-independent dual effect of trazodone on human cognition, with acute utilization associated with impaired cognitive function and long-term use with cognitive deterioration prevention. There was no evidence that trazodone could be used as an active treatment of neurodegenerative diseases itself, but the majority (n=12) of our findings indicate that it has no long-term cognitive detrimental effect. Future studies should explore trazodone's role in the UPR pathway and the implications in neurodegenerative diseases in humans.